UNSPSC 51182052: Methandriol diacetate

This classification denotes an anabolic steroid with the molecular formula C24H36O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z142SX9228, chemically known as androst-5-ene-3,17-diol, 17-methyl-, 3,17-diacetate, (3.beta.,17.beta.)-, but more generally known as methandriol diacetate, which bears US NIH Compound Identifier 102203. European Medicines Agency schedules methandriol diacetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08835MIG.

Most nations, for tariff purposes, schedule methandriol diacetate under HS 29372900. SMILES: CC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC[C@]4(C)OC(=O)C)C)C.

UNSPSC 51182052 Methandriol diacetate is a Commodity code capturing pharmaceutical active pharmaceutical ingredients and specialty chemical compounds procured through state and local cooperative purchasing alliances for distribution across government health facilities, correctional systems, and public health programs. State and local procurement under this code typically involves bulk purchases of generic pharmaceuticals and over-the-counter products negotiated through multistate cooperative frameworks that leverage aggregate demand to secure volume pricing and standardized supply-chain terms. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is the primary repeat buyer visible in current activity, using cooperative purchasing vehicles to aggregate demand across multiple participating jurisdictions and health systems.

MMCAP issued an RFP on January 20, 2026 (S1070000015802) for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026, requiring vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) with availability by May 15, 2026 and contract effectiveness July 1, 2026. The solicitation emphasizes price competitiveness (weighted 75 percent in evaluation), EDI capability, cGMP certification, and compliance with the Drug Supply Chain Security Act, with awarded vendors required to maintain $5 million commercial general liability coverage and $2 million network security and privacy liability coverage. Contract term runs two years for new responders with optional extensions, and incumbent responders' amendments extend through June 30, 2028. The RFP applies to participating state and local government facilities across Minnesota and Oregon without stated set-aside restrictions.